Emi Sugimoto, Jingmei Li, Yasutaka Hayashi, Kohei Iida, Shuhei Asada, Tsuyoshi Fukushima, Moe Tamura, Shiori Shikata, Wenyu Zhang, Keita Yamamoto, Kimihito Cojin Kawabata, Tatsuya Kawase, Takeshi Saito, Taku Yoshida, Satoshi Yamazaki, Yuta Kaito, Yoichi Imai, Tamami Denda, Yasunori Ota, Tomofusa Fukuyama, Yosuke Tanaka, Yutaka Enomoto, Toshio Kitamura, Susumu Goyama
Immunotherapy has attracted considerable attention as a therapeutic strategy for cancers including acute myeloid leukemia (AML). In this study, we found that the development of several aggressive subtypes of AML is slower in Rag2-/- mice despite the lack of B and T lymphocytes, even compared to the immunologically normal C57BL/6 mice. Furthermore, an orally active p53-activating drug shows stronger antileukemia effect on AML in Rag2-/- mice than C57BL/6 mice. Intriguingly, Natural Killer (NK) cells in Rag2-/- mice are increased in number, highly express activation markers, and show increased cytotoxicity to leukemia cells in a coculture assay...
December 21, 2023: Communications Biology